anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All admissions to the pediatric ICU of participant hospitals without restriction to age, gender or race/ethnicity. Patients who have previously consented under the Singapore Pediatric Intensive Care Registry (SG-PedIC) under a similar single-center study protocol which started from 2020 will also be included.
Disclosed in the present invention is a use of E-10-hydroxyl-2-decylenic acid in preparation of medicine or a health care product for preventing and treating osteoporosis. Active ingredient in the medicine or the health care product is only E-10-hydroxyl-2-decylenic acid, wherein the E-10-hydroxyl-2-decylenic acid is artificially synthesized or extracted from royal jelly. In the present invention, a novel use of E-10-hydroxyl-2-decylenic acid is disclosed for the first time. Experiment results prove that E-10-hydroxyl-2-decylenic acid has the obvious prevention and treatment effect on the osteoporosis, so that E-10-hydroxyl-2-decylenic acid can be used to the preparation of medicine or the health care product for preventing and treating osteoporosis. In addition, E-10-hydroxyl-2-decylenic acid is stable; can be simply prepared with low cost, and has homology of medicine and food. When E-10-hydroxyl-2-decylenic acid is used to prepare the medicine or the health care product for preventing and treating osteoporosis, it has the advantages of low cost, good prevention and treatment effect, low consumption, no toxic and side effects after long-time administration and the like. Moreover, wide application prospects are expected in the field of medicine or the health care product.
The invention discloses a traditional Chinese medicine for treating sciatica and lumbago. The traditional Chinese medicine for treating sciatica and lumbago disclosed by the invention is a medicament prepared from the vitis herba. The traditional Chinese medicine disclosed by the invention can be prepared by adopting a conventional traditional Chinese medicine method. The preparation method of power preferably comprises the steps of: placing cleaned and dried vitis herba into a pressure kettle to boil for 45 minutes; then drying and crushing into fine powder with 100 to 150 meshes. The dosage and the taking method of the traditional Chinese medicine are shown as follows: 50 g powder per dose each day is boiled with 800 to 1000 g water, and the powder is taken twice and respectively taken after a meal in the morning and after the meal in the evening. The disease can be cured through four doses of powder. The vitis herba is bitter in taste, and has the functions of dispelling wind and eliminating dampness, regulating channels and activating collaterals, relieving pain and spasmolysis, and relieving fatigue; and after use, the traditional Chinese medicine can dredge the channel, improve blood circulation, quickly remove sciatica and lumbago, and can repair diseased tissue due to sciatica, eliminate the rout cause of neuralgia, achieves once curing; and the traditional Chinese medicine has no toxic and side effects, can treat sciatica and lumbago, and has obvious curative effect.
Treatment in the intervention group will consist of intravenous acylated ghrelin, 600micrg dissolved in 50cc normal saline, by bolus (short term) infusion in 30 minutes, twice daily, for five days. This treatment will be additional to standard treatment, including intravenous thrombolysis, if indicated.
Knowledge of the reference interval of pulse oxygen saturation (SpO2) in neonates is crucial for accurate identification of neonatal hypoxemia. The now widely used standard was derived from low altitude data, which is not suitable neonates at high altitude. At present, many scholars have paid attention to this problem. But, previous studies still have some limitations. For example, they often only focus on a specific altitude. However, with the increase of altitude, the pulse oxygen saturation decreases in a curve, so their study results are only suitable for this specific altitude and can not be widely used.
USG was applied to the patients who underwent Laparoscopic sleeve gastrectomy for research trocar site hernia after 2-4 years from the surgery. Carter Thomasson suture passer was used to close fascial defect in all patients.
Single dose of JNT-517 suspension, JNT-517 tablet in a fasted state, and JNT-517 tablet in a fed state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.
The invention relates to the fields of natural medicine and medical care, specifically to Ribes diacanthum Pall. (RDP) and its application in preparation of anti-renal injury medicines. It proves through pharmacodynamic tests that Ribes diacanthum Pall. has a remarkable protective effect on cisplatin and unilateral uretereal obstruction induced renal injury. In addition, effective dose is low, and the Ribes diacanthum Pall. has no toxic or side effect. Thus, Ribes diacanthum Pall. can become an alternative medicine for preventing and curing renal disease.
Hypoxic pulmonary hypertension (HPH) is a serious and life-threatening chronic cardiopulmonary disease characterized by progressive elevation of pulmonary artery pressure and pulmonary vascular remodeling. Mesenchymal stem cell- derived exosomes (MSC-Exos) can relieve HPH by reversing pulmonary vascular remodeling. The HPH model was established in healthy male Sprague-Dawley (SD) rats aged 6 to 8 weeks. The rats were placed in a room with oxygen concentration of (10 ± 1) % for 8 hours a day over 28 days, were then injected intravenously with MSC-Exos (100 ug protein/kg) or equal-volume phosphate buffer saline (PBS) once a day over 1 week. Right ventricular systolic pressure (RVSP), right ventricular hypertrophy index (RVHI) and pulmonary vascular remodeling were observed after anesthesia. In addition, platelet-derived growth factor BB (PDGF-BB) was used to stimulate rat pulmonary artery smooth muscle cells (PASMCs) to construct HPH pathological cell models. The results showed that MSC-Exos could not only reduce the elevation of RVSP, right ventricular hypertrophy and the degree of pulmonary vascular remodeling in HPH rats, but also reduce the proliferation, migration and apoptosis resistance of PASMCs. Finally, GSE53408 and GSE113439 datasets were analyzed and showed that the expression of Hsp90aa1 and pERK/ERK were significantly increased in HPH, also could be inhibited by MSC-Exos. Meanwhile, inhibition of Hsp90aa1 also reduced PASMCs migration and pERK/ERK protein level. In conclusion, MSC-Exos alleviated HPH by suppressing PASMCs proliferation, migration and apoptosis resistance through inhibiting the Hsp90aa1/ERK/pERK pathway.
Rett syndrome (RTT) is the rare neurodevelopmental disorder caused by mutations in methyl CpG binding protein 2 (MECP2) gene with a prevalence of 1:10,000 worldwide. The hallmark clinical features of RTT are developmental delay, microcephaly, repetitive behaviours, gait abnormalities, respiratory abnormalities and seizures. Still, the understanding on the diagnosis of RTT among clinicians are less. The aim of our work was to study various clinical manifestations and a spectrum of MECP2 genetic heterogeneity in RTT patients from South Indian population. We screened 208 autistic patients and diagnosed 20 RTT patients, who were further divided into classical RTT (group I; N = 11) and variant RTT (group II; N = 9). The clinical severity of RTT was measured using RSSS, RSBQ, SSI, SSS and RTT gross motor scale. The biochemical analysis showed that thyroid-stimulating hormone (TSH), plasma dopamine and cholesterol levels were higher in group I when compared to group II, whereas the level of blood pressure, calcium, ferritin and high-density lipoprotein levels were significantly decreased in both RTT groups, when compared to the control group. The genetic mutational spectrum of MECP2 mutations were found in 12/20 of RTT patients, which revealed the occurrence of 60% pathogenic mutation and 20% unknown mutation and it was correlated with the clinical finding of respiratory dysfunction, scoliosis and sleeping problems. The significant results of this study provided clinical and genetic aspects of RTT diagnosis and proposed the clinicians to screen abnormal cholesterol, calcium and TSH levels tailed with MECP2 gene mutations for early prognosis of disease severity.
BACKGROUND: Vasovagal syncope (VVS) is a prevalent condition characterized by a sudden drop in blood pressure and heart rate, leading to a brief loss of consciousness and postural control. Recurrent episodes of VVS significantly impact the quality of life and are a common reason for emergency department visits. Non-pharmacological interventions, such as tilt training, physical counter pressure maneuvers, and yoga, have been proposed as potential treatments for VVS. However, their efficacy in preventing VVS remains uncertain.
METHODS: A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed, Web of Science, and Embase were searched up to March 2023 for randomized controlled trials comparing non-pharmacological interventions with control in preventing VVS recurrence. The primary outcome was the recurrence rate of VVS episodes.
RESULTS: A total of 1130 participants from 18 studies were included in the meta-analysis. The overall mean effect size for non-pharmacological interventions versus control was 0.245 (95 % CI: 0.128-0.471, p-value <0.001). Subgroup analysis showed that yoga had the largest effect size (odds ratio 0.068, 95 % CI: 0.018-0.250), while tilt training had the lowest effect size (odds ratio 0.402, 95 % CI: 0.171-0.946) compared to control. Physical counter pressure maneuvers demonstrated an odds ratio of 0.294 (95 % CI: 0.165-0.524) compared to control.
CONCLUSION: Non-pharmacological interventions show promise in preventing recurrent VVS episodes. Yoga, physical counter pressure maneuvers, and tilt training can be considered as viable treatment options. Further research, including randomized studies comparing pharmacological and non-pharmacological approaches, is needed to evaluate the safety and efficacy of these interventions for VVS treatment.
Participants received placebo matched to SCIT and subcutaneous (SC) injections of Dupilumab at a loading dose of 600 milligrams (mg) on Day 1, followed by a 300 mg for Q2W for 16 weeks. Both placebo matched to SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
The utility model provides a chitosan/N-Isopropyl acrylamide multi-hole medicine slow release microsphere. The shell of the microsphere adopts a porous structure, and the inner layer of the microsphere adopts a multi-core structure. The cores are powder medicine, namely resveratrol or pterostilbene. The shell is chitosan/N-Isopropyl acrylamide graft copolymer. The medicine formed after embedding the resveratrol or the pterostilbene is spheroidal powder with particle size of 15 to 80 micrometers, the dispersivity is excellent, the stability and the biocompatibility of medicine can be improved, and meanwhile, medicine slow release and medicine controlled release are achieved at the same time. The microsphere is low in biocompatibility, has less toxicity, and is helpful to improve the drug therapeutic effect of inner core. The slow release microsphere can be used as slow release powder when the resveratrol or the pterostilbene is wrapped by chitosan/ N-Isopropyl acrylamide.
PROBLEM TO BE SOLVED: To more appropriately inspect the presence or absence of the registration of the name of a disease corresponding to a prescribed medicine by registering a relation between the medicine and the name of an adapted disease in a disease name check master data base by a master code. SOLUTION: Master codes are read in order from the head of the maser code of the name of an adapted disease, which is obtained from the component group of the prescribed medicine stored in a memory 14. A medical treatment code maser 30 is retrieved by the code, the name of the corresponding disease is read and it is list-outputted. When the master code is not registered in the medical treatment code master 30, first disease code is taken out from the record of an adapted disease name master 50 and the master code of the medical treatment code master 30 is retrieved. When retrieval is hit, the record is read and the stored name is outputted as one adapted disease name. The processing is repeated until the prescribed number of adapted disease names are outputted.
Dietary supplement (Maziwa Mala) This is a type of cultured dairy milk, that is prepared through mesophilic fermentation of milk that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
This trial is a prospective, single-center, single-arm clinical research. Based on current experience, single agent immunotherapy has limited efficacy in advanced melanoma. SHR-1701 is a novel immunotherapy drug . Preclinical data suggest that temozolomide selectively depletes regulatory T cells. This potential immunomodulatory effect of temozolomide provides rationale for combination with SHR-1701. This study is aiming to evaluate the efficacy and safety of SHR-1701 combined with temozolomide in patients with advanced melanoma. The safety and efficacy of this study will be assessed through ORR, DCR,PFS, OS , and adverse effects as graded by CTCAE 5.0.
Up to 20 people with current or recent experience of using community-based mental health services will be recruited to the study. Participants will take part in one in-depth interview or focus group discussion.
PURPOSE: The incidence of peri-implant femoral fractures (PIFF) is increasing. Information regarding outcomes, timing of surgery, risk factors, and a clinically applicable treatment algorithm are lacking. The aim of this study was to identify outcome-related risk factors and to derive a treatment algorithm.
METHODS: Sixty-four PIFFs treated between 01.01.2006 and 31.12.2020 in a level I trauma centre were evaluated retrospectively for fracture pattern, surgical technique, risk factors, complications, and 1-year mortality. The study was approved by the ethics committee (No. 21-2714-104).
RESULTS: One-year mortality was 24.1%. Surgical complications occurred in 4.7%, and general complications in 15.6% of the patients. General complications, low haemoglobin level at admission, elevated CHA2DS2-VASc, and Charlson score resulted in increased 1-year mortality. Time to surgery > 24 h did not increase complication or mortality rates. The three predominant fracture patterns were fractures close or distal to cephalomedullary nails, close or proximal to distal lateral plates, and close or distal to sliding hip screws. Recommendations for surgical treatment were derived: Osteosynthesis should enable as much weight-bearing as possible; the initial implant should only be removed, if this is essential for the new osteosynthesis; lateral locking plates should span the whole femur; antegrade nails should have a cephalomedullary component to avoid consecutive femoral neck fractures; implants should overlap to reduce the risk of consecutive inter-implant fractures.
CONCLUSION: Risk factors for 1-year mortality in patients with PIFFs were identified. A treatment algorithm and general principles for surgery of PIFFs were developed.
The invention relates to a yin-yang plaster. The yin-yang plaster comprises a plaster body and a back lining layer, wherein the plaster body comprises matrix, bulk pharmaceutical chemicals and a percutaneous absorption promoter. The yin-yang plaster is characterized in that the plaster body consists of a yin plaster body and a yang plaster body which are mutually closed and are pasted on the back lining layer, wherein the weight ratio of the yin plaster body to a white matrix vector to growing, yin and cold kinds of the bulk pharmaceutical chemicals is 10:3; and the weight ratio of the yang plaster body to a black matrix vector to antiphlogistic, yang and hot kinds of the bulk pharmaceutical chemicals is 10:3. The white matrix vector component contains 90 to 95 percent of white matrix and 5 to 10 percent of borneol; the black matrix vector component contains 90 to 95 percent of black matrix contained and 5 to 10 percent of musk; the white matrix component contains 10 percent of white oil-soluble pigment and 90 percent of medical pressure-sensitive adhesive; and the black matrix component contains 10 percent of black oil-soluble pigment and 90 percent of medical pressure-sensitive adhesive. The yin-yang plaster has a shape of two fishes in a Taiji diagram, a symmetrical double semi-circular shape or a symmetrical square shape. The yin-yang plaster has the following advantages of obvious effects of curing diseases and removing pain, and long medicament effect.
An objective of the present invention is to provide safe viral vectors for gene therapy that can be introduced by a simple technique and sufficiently express genes of interest  in vivo.  The present inventors demonstrated that anti-tumor effect can be produced when a heparin-binding cytokine such as granulocyte macrophage colony stimulating factor (GM-CSF) and a chemokine such as TARC or RANTES are expressed  in vivo  using a viral vector based on a negative-strand RNA virus. The present inventors also demonstrated that the protective effect of the vector is superior to that of conventional adenovirus vectors. Thus, the present invention relates to negative-strand RNA viral vectors comprising a cytokine gene and a chemokine gene. The viral vectors are suitable for treatment of cancers, in particular, metastatic cancers. The present invention also provides compositions comprising such viral vectors, and gene therapy methods using them.
In spite of the pronounced benefit of kidney transplantation in prolonging survival and improving the quality of life of patients with end stage renal disease, it is still hampered by the risk of graft rejection and the need for lifelong immunosuppression. Researchers have sought to circumvent these challenges through the use of combined kidney and hematopoietic stem cell transplantation to induce immune tolerance. This study will build upon published reports showing favorable results for the TLI/rATG regimen in HLA-matched living donor transplant recipients. The investigators seek to confirm that patients treated with total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG) followed by human leukocyte antigen (HLA)-identical donor hematopoietic progenitor cell transplant can be withdrawn from immunosuppressive drugs while maintaining normal renal function after renal transplantation. At serial time points, (1) graft function will be monitored, (2) chimerism will be measured in recipient white blood cell subsets, and (3) protocol biopsies of the graft will be obtained. An attempt will be made to discontinue tacrolimus at 12 months if the following conditions are met: (1) chimerism (defined as ≥5% donor type cells among the T cells, B cells, Natural Killer \[NK\] cells, and granulocytes) is detectable for at least 180 days after CD34+ and CD3+ cell infusion, (2) stable graft function without clinical rejection episodes is maintained, (3) there is lack of histologic rejection on protocol biopsies, and (4) there is no evidence of graft vs. host disease (GVHD). Recipients in the proposed study will be given a target dose of ≥ 5 x106 CD34+ cells/kg and 5x106 CD3+ cells/kg with the goal of achieving durable mixed chimerism.
Use is claimed of ester polyol compounds as solvents, solvent aids or dispersion aids for organic compounds or pharmaceuticals, cosmetics, detergents, food or agrochemical agents which are poorly soluble or insoluble in lipophilic and hydrophilic media and as dispersants or continuous phases for pigment and micropigment dispersions. Use is claimed of ester polyol compounds as solvents, solvent aids or dispersion aids for organic compounds or pharmaceuticals, cosmetics, detergents, food or agrochemical agents which are poorly soluble or insoluble in lipophilic and hydrophilic media and as dispersants or continuous phases for pigment and micropigment dispersions. The ester polyol compounds are optionally in admixture with amino-functional polyol compounds of melting point below 100[deg]C or ester polyol compounds of formula R 1>-O-[EO] n[PO-] mR 2>(I) and are derived from: (a) polyol components comprising glycerol, 2-20C alkylene glycols, poly(2-20C alkylene)glycols (e.g. ethylene glycol or polyethylene glycols in which upto 30% of the ethylene oxide units are replaced by propylene oxide units), polyglycerols, sorbitol or pentaerythritol, and (b) acid components comprising aliphatic 3-6C carboxylic acids containing, in addition to carboxylic acid groups, hydroxy or carboxy groups. R 1>1-4C alkyl; R 2>H or 1-4C alkyl; n : 1-100; m : 0-n/2; EO : ethylene oxide, and PO : propylene oxide. Independent claims are also included for: (1) solutions of the organic compounds in the lipophilic and hydrophilic media; (2) dispersions of pigments and micropigments or the organic compounds in the ester polyol compounds, and (3) ester polyol/polyol-in-oil emulsions or dispersions with an oil-immiscible ester polyol/polyol phase, an oil phase and an emulsifier.
Sexually transmitted infections (STIs) are a major public health problem worldwide, with a high prevalence between the ages of 15 and 25 in most Western countries. High notification rates of chlamydia, gonorrhea, and syphilis are reported in the WHO European Region, with differences between countries. In Italy, the total number of STIs alerts increased by 18% from 2020 to 2021. HPV is the most common sexually transmitted infection; globally one in seven women is infected by this virus, and certain sexual behaviors are important risk factors for HPV-related cancers, particularly cervical cancer (CC), anogenital cancers and cancers of the head and neck. The burden of CC is relevant worldwide, in particular in Europe CC is the third leading cause of cancer-related deaths in women aged 15-44. This HPV-related tumor is preventable through a combined strategy of vaccination and screening for precursor lesions. In Italy, the coverage of organized screening varies from region to region and the average HPV vaccination rate is still far from the expected optimal threshold of 95% at the age of 12. To address the challenges of health promotion and HPV prevention, priority actions are needed such as: promoting education and information at every level, from schools to healthcare professionals. In Italy, education of adolescents on sexual and reproductive health, still remains critical, regionally inhomogeneous and much lower than in other European countries. Equitable measures need to be taken, and schools are an important place for health promotion activities.